Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02727972 · ClinicalTrials.gov registry record · NA

Examination of Glutamate and mGluR5 in Psychiatric Disorders

A NA study of Major Depressive Disorder and Bipolar Disorder, sponsored by Yale University.

Completed
Registry status
NA
Development phase
180
Enrollment target
1
Study location

NCT02727972 is a NA study of Major Depressive Disorder and Bipolar Disorder that has completed, run by Yale University. The registered enrollment target is 180 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02727972, a NA study of Major Depressive Disorder and Bipolar Disorder, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

This research study is designed to look at the involvement of the glutamate system in depression. Each subject will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availability and will consist of one MRI scan, and PET scan. Subjects will also participate in cognitive testing. Depending on camera time, staff availability and subject schedule, total study participation may last 1-2 months.

Interventions

  • OTHER MRI
  • BEHAVIORAL Cognitive Testing
  • RADIATION PET

Study Locations (1)

Connecticut

  • PET Center - New Haven

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2012-02-21
Est. Completion 2022-01-13
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT02727972

The ClinicalTrials.gov registry entry for NCT02727972 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (52% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 3 interventions - of which MRI is the first listed.

NCT02727972 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT02727972 about?

NCT02727972 is a clinical study titled "Examination of Glutamate and mGluR5 in Psychiatric Disorders". This research study is designed to look at the involvement of the glutamate system in depression. Each subject will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availability and will consist of one MRI scan, and P...

What is the current status of trial NCT02727972?

This trial is currently completed. It is a NA study. The enrollment target is 180 participants. The study started on 2012-02-21. Estimated completion is 2022-01-13.

What conditions does trial NCT02727972 study?

This clinical trial studies the following conditions: Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder.

What interventions are being tested in trial NCT02727972?

The interventions under investigation include: MRI (OTHER), Cognitive Testing (BEHAVIORAL), PET (RADIATION).

Who is sponsoring clinical trial NCT02727972?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02727972 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.